- Home
- LYEL vs DRUG Comparison
LYEL vs DRUG Comparison
Compare LYEL & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LYEL
- DRUG
- Stock Information
- Founded
- LYEL 2018
- DRUG 2019
- Country
- LYEL United States
- DRUG United States
- Employees
- LYEL N/A
- DRUG N/A
- Industry
- LYEL Biotechnology: Pharmaceutical Preparations
- DRUG Pharmaceuticals and Biotechnology
- Sector
- LYEL Health Care
- DRUG Health Care
- Exchange
- LYEL Nasdaq
- DRUG Nasdaq
- Market Cap
- LYEL 263.9M
- DRUG 260.6M
- IPO Year
- LYEL 2021
- DRUG N/A
- Fundamental
- Price
- LYEL $0.62
- DRUG $38.77
- Analyst Decision
- LYEL Sell
- DRUG Buy
- Analyst Count
- LYEL 2
- DRUG 1
- Target Price
- LYEL $1.00
- DRUG $75.00
- AVG Volume (30 Days)
- LYEL 1.5M
- DRUG 155.7K
- Earning Date
- LYEL 11-07-2024
- DRUG 02-11-2025
- Dividend Yield
- LYEL N/A
- DRUG N/A
- EPS Growth
- LYEL N/A
- DRUG N/A
- EPS
- LYEL N/A
- DRUG N/A
- Revenue
- LYEL $63,000.00
- DRUG N/A
- Revenue This Year
- LYEL N/A
- DRUG N/A
- Revenue Next Year
- LYEL N/A
- DRUG N/A
- P/E Ratio
- LYEL N/A
- DRUG N/A
- Revenue Growth
- LYEL N/A
- DRUG N/A
- 52 Week Low
- LYEL $0.58
- DRUG $0.93
- 52 Week High
- LYEL $3.26
- DRUG $79.02
- Technical
- Relative Strength Index (RSI)
- LYEL 27.76
- DRUG 50.21
- Support Level
- LYEL $0.58
- DRUG $36.35
- Resistance Level
- LYEL $0.95
- DRUG $42.85
- Average True Range (ATR)
- LYEL 0.07
- DRUG 3.95
- MACD
- LYEL -0.02
- DRUG -0.43
- Stochastic Oscillator
- LYEL 6.48
- DRUG 22.76
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.